Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 27955 | 178 | 39.3 | 93% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | CD83 | Author keyword | 20 | 37% | 24% | 43 |
| 2 | SOLUBLE CD83 | Author keyword | 11 | 100% | 3% | 6 |
| 3 | MARCH I | Author keyword | 3 | 100% | 2% | 3 |
| 4 | HUMAN CD83 | Author keyword | 1 | 100% | 1% | 2 |
| 5 | INTEGRAT INFECT IMMUN | Address | 1 | 100% | 1% | 2 |
| 6 | RING CH | Author keyword | 1 | 100% | 1% | 2 |
| 7 | SCD83 | Author keyword | 1 | 100% | 1% | 2 |
| 8 | IMMUNE MODULAT | Address | 1 | 18% | 4% | 7 |
| 9 | ALLOGENE TRANSPLANTAT CLIN IMMUNOL SERV | Address | 1 | 50% | 1% | 1 |
| 10 | CHRON IMMUNE REACT | Address | 1 | 50% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | CD83 | 20 | 37% | 24% | 43 | Search CD83 | Search CD83 |
| 2 | SOLUBLE CD83 | 11 | 100% | 3% | 6 | Search SOLUBLE+CD83 | Search SOLUBLE+CD83 |
| 3 | MARCH I | 3 | 100% | 2% | 3 | Search MARCH+I | Search MARCH+I |
| 4 | HUMAN CD83 | 1 | 100% | 1% | 2 | Search HUMAN+CD83 | Search HUMAN+CD83 |
| 5 | RING CH | 1 | 100% | 1% | 2 | Search RING+CH | Search RING+CH |
| 6 | SCD83 | 1 | 100% | 1% | 2 | Search SCD83 | Search SCD83 |
| 7 | GAMMA HERPESVIRUS 68 | 1 | 50% | 1% | 1 | Search GAMMA+HERPESVIRUS+68 | Search GAMMA+HERPESVIRUS+68 |
| 8 | HUMAN CD83 HCD83 | 1 | 50% | 1% | 1 | Search HUMAN+CD83+HCD83 | Search HUMAN+CD83+HCD83 |
| 9 | INHIBITORY REGULATION | 1 | 50% | 1% | 1 | Search INHIBITORY+REGULATION | Search INHIBITORY+REGULATION |
| 10 | MARCH1 | 1 | 50% | 1% | 1 | Search MARCH1 | Search MARCH1 |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | SOLUBLE CD83 | 67 | 87% | 19% | 33 |
| 2 | MURINE CD83 | 30 | 100% | 7% | 12 |
| 3 | EXPRESS CD83 | 11 | 67% | 6% | 10 |
| 4 | C MIR | 5 | 63% | 3% | 5 |
| 5 | CD83 EXPRESSION | 3 | 45% | 3% | 5 |
| 6 | ACTIVATED DENDRITIC CELLS | 2 | 33% | 3% | 5 |
| 7 | MARCH II | 1 | 38% | 2% | 3 |
| 8 | MARCH I | 1 | 100% | 1% | 2 |
| 9 | CD83 | 1 | 14% | 3% | 5 |
| 10 | GOLGI RIBBON | 1 | 50% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| CD83 regulates lymphocyte maturation, activation and homeostasis | 2008 | 40 | 63 | 71% |
| Dendritic cell CD83: A therapeutic target or innocent bystander? | 2008 | 24 | 45 | 80% |
| Control of MHC II antigen presentation by ubiquitination | 2013 | 7 | 52 | 44% |
| The trafficking and regulation of membrane receptors by the RING-CH ubiquitin E3 ligases | 2009 | 48 | 53 | 30% |
| Regulation of VEIC class II-peptide complex expression by ubiquitination | 2013 | 3 | 29 | 52% |
| MARCH-I: A new regulator of dendritic cell function | 2010 | 7 | 22 | 55% |
| Targeting CD83 for the treatment of graft-versus-host disease (Review) | 2013 | 2 | 54 | 50% |
| How to target MHC class II into the MIIC compartment | 2013 | 3 | 20 | 40% |
| The ins and outs of MHC class II-mediated antigen processing and presentation | 2015 | 2 | 148 | 14% |
| CD83: an update on functions and prospects of the maturation marker of dendritic cells | 2007 | 52 | 101 | 29% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INTEGRAT INFECT IMMUN | 1 | 100% | 1.1% | 2 |
| 2 | IMMUNE MODULAT | 1 | 18% | 3.9% | 7 |
| 3 | ALLOGENE TRANSPLANTAT CLIN IMMUNOL SERV | 1 | 50% | 0.6% | 1 |
| 4 | CHRON IMMUNE REACT | 1 | 50% | 0.6% | 1 |
| 5 | CLIN COOPERAT GRP PEDIAT ONCOL | 1 | 50% | 0.6% | 1 |
| 6 | FUNCT GEN GRP | 1 | 50% | 0.6% | 1 |
| 7 | INTEGRAT INFECT IMMUNOL | 1 | 50% | 0.6% | 1 |
| 8 | LONDON HLTH SCI SURG | 1 | 50% | 0.6% | 1 |
| 9 | ROSALIND FRANKLIN GEN | 1 | 50% | 0.6% | 1 |
| 10 | SANDLER ASTHMA BASIC | 1 | 13% | 2.2% | 4 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000099262 | DENDRITIC CELLS//DENDRITIC CELL//TUMOR LYSATE |
| 2 | 0.0000086560 | INVARIANT CHAIN//HLA DM//ANTIGEN PROCESSING |
| 3 | 0.0000083336 | DSK2//UBIQUILIN 1//LUBAC |
| 4 | 0.0000074231 | CROSS PRESENTATION//CHRIS BROWNE IMMUNOL IMMUNE DIS//CD207 |
| 5 | 0.0000073107 | UNITA OPERAT ASSISTENZIALE GINECOL ONCOL//CD1A//CDLA |
| 6 | 0.0000072572 | PRIMARY EFFUSION LYMPHOMA//KSHV//TUMOR VIROL PROGRAM |
| 7 | 0.0000068963 | PARAPTOSIS//BAP31//MEMBRANE BLEBS |
| 8 | 0.0000065077 | ESCRT//ALG 2//TSG101 |
| 9 | 0.0000063047 | HYPUSINE//EIF5A//EIF 5A |
| 10 | 0.0000061977 | EVOLUTIONARY IMMUNOBIOL//PERITONEAL INFLAMMATION//EVOLUT IMMUNOBIOL |